JP7832926B2 - 制約され、条件付きで活性化された結合タンパク質 - Google Patents

制約され、条件付きで活性化された結合タンパク質

Info

Publication number
JP7832926B2
JP7832926B2 JP2023511947A JP2023511947A JP7832926B2 JP 7832926 B2 JP7832926 B2 JP 7832926B2 JP 2023511947 A JP2023511947 A JP 2023511947A JP 2023511947 A JP2023511947 A JP 2023511947A JP 7832926 B2 JP7832926 B2 JP 7832926B2
Authority
JP
Japan
Prior art keywords
sdabd
seq
domain
epcam
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023511947A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023538366A (ja
JP2023538366A5 (enExample
Inventor
ビー ダブリッジ，ロバート
ティモシー チェン，ツェン－ホイ
エイ カルプ，パトリシア
マイケル メイ，チャド
デットリング，ダニエル
デゲンハート，ジェレミア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2023538366A publication Critical patent/JP2023538366A/ja
Publication of JP2023538366A5 publication Critical patent/JP2023538366A5/ja
Application granted granted Critical
Publication of JP7832926B2 publication Critical patent/JP7832926B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2023511947A 2020-08-17 2021-08-17 制約され、条件付きで活性化された結合タンパク質 Active JP7832926B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063066565P 2020-08-17 2020-08-17
US63/066,565 2020-08-17
PCT/US2021/046217 WO2022040128A2 (en) 2020-08-17 2021-08-17 Constrained conditionally activated binding proteins

Publications (3)

Publication Number Publication Date
JP2023538366A JP2023538366A (ja) 2023-09-07
JP2023538366A5 JP2023538366A5 (enExample) 2024-08-22
JP7832926B2 true JP7832926B2 (ja) 2026-03-18

Family

ID=77655705

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023511947A Active JP7832926B2 (ja) 2020-08-17 2021-08-17 制約され、条件付きで活性化された結合タンパク質

Country Status (16)

Country Link
US (1) US20240026011A1 (enExample)
EP (1) EP4196503A2 (enExample)
JP (1) JP7832926B2 (enExample)
KR (1) KR20230048146A (enExample)
CN (1) CN116419925A (enExample)
AR (1) AR123266A1 (enExample)
AU (1) AU2021329290A1 (enExample)
CA (1) CA3191431A1 (enExample)
CL (1) CL2023000477A1 (enExample)
CO (1) CO2023002164A2 (enExample)
EC (1) ECSP23018458A (enExample)
IL (1) IL300598A (enExample)
MX (1) MX2023002002A (enExample)
PE (1) PE20230856A1 (enExample)
TW (1) TW202214707A (enExample)
WO (1) WO2022040128A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12128102B2 (en) 2016-03-08 2024-10-29 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins
CN111356700A (zh) 2017-09-08 2020-06-30 马弗里克治疗公司 受约束的条件性活化的结合蛋白
WO2023164551A1 (en) * 2022-02-23 2023-08-31 Takeda Pharmaceutical Company Limited Conditionally bispecific binding proteins
WO2024040220A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding fusion proteins
WO2024040228A2 (en) * 2022-08-19 2024-02-22 Regents Of The University Of Minnesota Cd83 binding proteins
WO2024051762A1 (en) * 2022-09-07 2024-03-14 Xadcera Biopharmaceutical (Suzhou) Co., Ltd. Anti-trop2/egfr antibodies and uses thereof
EP4646436A2 (en) * 2023-01-05 2025-11-12 Harpoon Therapeutics, Inc. Trop2 targeting trispecific protein for treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190076524A1 (en) 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY167125A (en) 2011-08-17 2018-08-13 Glaxo Group Ltd Modified proteins and peptides
AU2017229687A1 (en) 2016-03-08 2018-09-20 Takeda Pharmaceutical Company Limited Inducible binding proteins and methods of use
EP4592313A3 (en) 2019-03-05 2025-11-19 Takeda Pharmaceutical Company Limited Constrained conditionally activated binding proteins

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190076524A1 (en) 2017-09-08 2019-03-14 Maverick Therapeutics, Inc. Constrained conditionally activated binding proteins

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHABROL, E. et al.，Anal Biochem，2020年01月15日，Vol. 589: 113491

Also Published As

Publication number Publication date
JP2023538366A (ja) 2023-09-07
IL300598A (en) 2023-04-01
US20240026011A1 (en) 2024-01-25
AU2021329290A1 (en) 2023-04-13
KR20230048146A (ko) 2023-04-10
CL2023000477A1 (es) 2023-11-10
AR123266A1 (es) 2022-11-16
WO2022040128A3 (en) 2022-04-07
EP4196503A2 (en) 2023-06-21
ECSP23018458A (es) 2023-04-28
TW202214707A (zh) 2022-04-16
MX2023002002A (es) 2023-07-06
PE20230856A1 (es) 2023-05-29
CN116419925A (zh) 2023-07-11
CA3191431A1 (en) 2022-02-24
CO2023002164A2 (es) 2023-03-07
WO2022040128A2 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
JP7826370B2 (ja) 拘束され、条件的に活性化された結合タンパク質
JP7707360B2 (ja) 拘束され、条件的に活性化された結合タンパク質
JP2023538366A (ja) 制約され、条件付きで活性化された結合タンパク質
JP2023540533A (ja) ヒト血清アルブミンドメインを有する、制約され、条件付きで活性化された結合タンパク質構築物
US20230340159A1 (en) Constrained conditionally activated binding proteins
US12128102B2 (en) Constrained conditionally activated binding proteins
EA049569B1 (ru) Ограниченные условно активируемые связывающие белки
HK40032913A (en) Constrained conditionally activated binding proteins
EA045012B1 (ru) Ограниченные условно активируемые связывающие белки

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240814

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250930

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251126

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260217

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260306

R150 Certificate of patent or registration of utility model

Ref document number: 7832926

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150